Platelet to white blood cell ratio was an independent prognostic predictor in acute myeloid leukemia

Figures & data

Figure 1. Survival analyses of patients with CN-AML. Kaplan–Meier estimates of OS (A) and EFS (B) by low, intermediate, and high groups for CN-AML patients, respectively.

Table 1. Clinical characteristics of CN-AML with distinct level of PWR.

Variables	Low group	Intermediate group	High group	P value
Number	113	112	113
PWR, median (IQR)	0.52 [0.31,0.90]	3.76 [2.49,5.27]	25.38 [13.14,56.15]	<0.001
Age, median (range), years	48.00 [34.00,61.00]	52.50 [44.00,61.25]	53.00 [42.00,63.00]	0.108
Sex, male, n (%)	64 (56.6)	66 (58.9)	59 (52.2)	0.593
BM blast, median (IQR), %^1	70.00 [46.38,82.75]	59.00 [44.25,78.25]	53.00 [36.00,75.00]	0.013
WBC, median (IQR), ×10^9/L^2	69.80 [27.10,137.70]	11.65 [6.15,21.02]	2.40 [1.30,5.10]	<0.001
HB, median (IQR), g/L^3	86.00 [70.00,98.00]	82.00 [64.00,101.25]	87.00 [69.00,105.00]	0.647
PLT, median (IQR),×10^9/L^4	32.00 [17.00,52.00]	44.00 [26.00,77.25]	88.00 [48.00,138.00]	<0.001
FAB classification, n(%)^5				0.178
M0	5(4.4)	10(8.9)	18(15.9)
M1	10(8.8)	6(5.4)	6(5.3)
M2	58(51.3)	49(43.8)	54(47.8)
M4	6(5.3)	4(3.6)	2(1.8)
M5	32(28.3)	41(36.6)	29(25.7)
M6	0(0.0)	1(0.9)	1(0.9)
Gene mutations, n (%)
FLT3-ITD	42(37.8)	17(15.2)	14(12.5)	<0.001
NPM1	33(29.7)	26(23.9)	17(15.5)	0.038
CEBPA^DM6	18(16.7)	13(12.0)	11(10.3)	0.399
DNMT3A	16(15.1)	17(16.0)	14(13.0)	0.816
ELN favorable genotype	28 (25.2)	26 (23.4)	20 (18.0)	0.407
Treatment
IA regimen	99 (87.6)	104 (92.9)	94 (83.2)	0.084
DA regimen	14(12.4)	8(7.1)	19(16.8)
BMT	14 (12.4)	17 (15.2)	17 (15.0)	0.795

¹BM, bone marrow; ²WBC, white blood cell; ⁴HB, hemoglobin; ⁴PLT, platelet counts; ⁵FAB, French–American–British classification systems; ⁶DM: Double-allele. IQR, interquartile range. European Leukemia Net (ELN) favorable genotype is defined as mutated NPM1 without FLT3-ITD and CEBPA double allele mutations. BMT, bone marrow transplantation. DA, daunorubicin 45-60 mg/m² daily for 3 days and cytarabine 100 mg/m² daily for 7 days; IA, idarubicin 8–10 mg/m² daily for 3 days and cytarabine 100 mg/m² daily for 7 days.

Figure 2. Values of PWR alone(A and D), molecular (ELN genetic subtypes and DNMT3A mutations) predictors (B and E), and PWR combined molecular predictors (C and F) in predicting 1-, 3-, and 5-year survival in OS and EFS.

Figure 3. Multivariable survival analyses of OS (A) and EFS (B) for CN-AML patients, respectively.